Document:

<PAGE>

                                                                   Exhibit 10.29
                            STOCK PURCHASE AGREEMENT

Endocardial Solutions, Inc.
1350 Energy Lane, Suite 110
St. Paul, Minnesota 55108

The undersigned (the "INVESTOR"), hereby confirms its agreement with you as
follows:

1. This Stock Purchase Agreement (the "AGREEMENT") is made as of the date set
forth below among Endocardial Solutions, Inc., a Delaware corporation (the
"COMPANY"), and the Investor.

2. The Company has authorized the sale and issuance of up to 2,449,666 shares
(the "SHARES") of common stock of the Company, $.01 par value per share (the
"COMMON STOCK"), to certain investors in a private placement (the "OFFERING").

3. The Company and the Investor agree that the Investor will purchase from
the Company and the Company will issue and sell to the Investor _______
Shares at a purchase price of $3.00 per Share, or an aggregate purchase price
of $____________________, pursuant to the Terms and Conditions for Purchase
of Shares attached hereto as Annex I and incorporated herein by this
reference as if fully set forth herein. Unless otherwise requested by the
Investor in Exhibit A, certificates representing the Shares purchased by the
Investor will be registered in the Investor's name and address as set forth
below.

4. The Investor represents that, except as set forth below, (a) it has had no
position, office or other material relationship within the past three years
with the Company or its affiliates, (b) neither it, nor any group of which it
is a member or to which it is related, beneficially owns (including the right
to acquire or vote) any securities of the Company and (c) it has no direct or
indirect affiliation or association with any National Association of
Securities Dealers, Inc. ("NASD") member. Exceptions:

--------------------------------------------------------------------------------
     (If no exceptions, write "none." If left blank, response will be
                          deemed to be "none.")

<PAGE>

Please confirm that the foregoing correctly sets forth the agreement between
us by signing in the space provided below for that purpose.

                                 DATED AS OF:  March 22, 2001

                                 ---------------------------------------------
                                 "INVESTOR"

                                 By:
                                     -----------------------------------------
                                 Print Name:
                                            ----------------------------------
                                 Title:
                                         -------------------------------------
                                 Address:
                                           -----------------------------------
                                  --------------------------------------------

AGREED AND ACCEPTED:
Endocardial Solutions, Inc.

By:  JAMES W. BULLOCK
   --------------------------------------------
Title:  PRESIDENT AND CHIEF EXECUTIVE OFFICER
    --------------------------------------------

                                       2
<PAGE>

                                    ANNEX I

                   TERMS AND CONDITIONS FOR PURCHASE OF SHARES

         1.       AGREEMENT TO SELL AND PURCHASE THE SHARES; SUBSCRIPTION
                  DATE.

                  1.1 PURCHASE AND SALE. At the Closing (as defined in
Section 2), the Company will sell to the Investor, and the Investor will
purchase from the Company, upon the terms and conditions hereinafter set
forth, the number of Shares set forth in paragraph 3 of the Stock Purchase
Agreement to which these Terms and Conditions for Purchase of Shares are
attached as Annex I and at the purchase price set forth in such paragraph.

                  1.2 OTHER INVESTORS. As part of the Offering, the Company
proposes to enter into this same form of Stock Purchase Agreement with
certain other investors (the "OTHER INVESTORS"), and the Company expects to
complete sales of Shares to them. (The Investor and the Other Investors are
hereinafter sometimes collectively referred to as the "INVESTORS," and this
Agreement and the Stock Purchase Agreements executed by the Other Investors
are hereinafter sometimes collectively referred to as the "AGREEMENTS.") The
Company will accept executed Agreements from Investors for the purchase of
Shares commencing upon the date on which the Company provides the Investors
with the proposed purchase price per Share and concluding upon the date (the
"SUBSCRIPTION DATE") on which the Company has notified U.S. Bancorp Piper
Jaffray Inc. (in its capacity as Placement Agent for the Shares, the
"PLACEMENT AGENT") in writing that it is no longer accepting Agreements for
the purchase of Shares in the Offering.

                  1.3 PLACEMENT AGENT FEE. Investor acknowledges that the
Company intends to pay the Placement Agent a fee in respect of the sale of
Shares to the Investor.

         The Company shall indemnify and hold harmless the Investor from and
against all fees, commissions or other payments owing by the Company to the
Placement Agent or any other person or firm acting on behalf of the Company
hereunder.

         2. DELIVERY OF THE SHARES AT CLOSING. The completion of the purchase
and sale of the Shares (the "CLOSING") shall occur at a place and time, no
later than March 26, 2001 (the "CLOSING DATE"), to be specified by the
Company and the Placement Agent, and of which the Investors will be notified
in advance by the Placement Agent. At the Closing, the Company shall deliver
to the Investor one or more stock certificates representing the number of
Shares set forth on the signature page hereto, each such certificate to be
registered in the name of the Investor or, if so indicated on the Stock
Certificate Questionnaire attached hereto as Exhibit A, in the name of a
nominee designated by the Investor provided that, if requested by the
Investor, stock certificates representing such Shares shall be delivered in
escrow to such Investor's agent prior to the Closing, to be held until the
completion of the Closing. In addition, on or prior to the Closing Date, the
Company shall cause counsel to the Company to deliver to the Investors a
legal opinion in the form attached hereto as Exhibit D.

         The Company's obligation to issue and sell the Shares to the
Investor shall be subject to the following conditions, any one or more of
which may be waived by the Company: (a) receipt by the Company of the
purchase price for the Shares being purchased hereunder as set forth on the
Signature Page hereto; (b) completion of purchases and sales under the
Agreements with the Other Investors; and (c) the accuracy of the
representations and warranties made by the Investors and the fulfillment of
those undertakings of the Investors to be fulfilled prior to the Closing.

                                       1
<PAGE>

         The Investor's obligation to purchase the Shares shall be subject to
the following conditions, any one or more of which may be waived by the
Investor: (a) the Company's agreement to issue and sell, and the Investors'
agreement to purchase, on the Closing Date, not less than one million
(1,000,000) shares of Common Stock; (b) the delivery to the Investor by
counsel to the Company of a legal opinion in the form attached hereto as
Exhibit D; (c) the representations and warranties of the Company contained in
Section 3 being true and correct on and as of such Closing with the same
effect as though such representations and warranties had been made on and as
of the date of such Closing; (d) the absence of any order, writ, injunction,
judgment or decree that questions the validity of the Agreements or the right
of the Company to enter into such Agreements or to consummate the
transactions contemplated hereby and thereby; and (e) the delivery to the
Investor by the Secretary or Assistant Secretary of the Company of a
certificate stating that the condition specified in part (c) of this
paragraph has been fulfilled.

         3. REPRESENTATIONS, WARRANTIES AND COVENANTS OF THE COMPANY. Except
as otherwise described in the Company's Annual Report on Form 10-K for the
year ended December 31, 1999 (and any amendments thereto filed prior to the
date hereof), the Company's Proxy Statement for its 2000 Annual Meeting of
Stockholders, or the Company's Quarterly Reports on Form 10-Q for the
quarters ended March 31, 2000, June 30, 2000 and September 30, 2000 or any of
the Company's Current Reports on Form 8-K filed since January 1, 2000
(collectively, the "SEC REPORTS"), the Company hereby represents and warrants
to, and covenants with, the Investor as of the date hereof and the Closing
Date, as follows:

                  3.1 ORGANIZATION. The Company is duly incorporated and
validly existing in good standing under the laws of the jurisdiction of its
organization. The Company has full power and authority to own, operate and
occupy its properties and to conduct its business as presently conducted and
is registered or qualified to do business and in good standing in each
jurisdiction in which it owns or leases property or transacts business and
where the failure to be so qualified would have a material adverse effect
upon the Company, or the business, financial condition, properties,
operations or assets of the Company, or the Company's ability to perform its
obligations under the Agreements ("MATERIAL ADVERSE EFFECT"), and no
proceeding has been instituted in any such jurisdiction revoking, limiting or
curtailing, or seeking to revoke, limit or curtail, such power and authority
or qualification. The Company has no subsidiaries.

                  3.2 DUE AUTHORIZATION. The Company has all requisite power
and authority to execute, deliver and perform its obligations under the
Agreements, and the Agreements have been duly authorized and validly executed
and delivered by the Company and constitute legal, valid and binding
agreements of the Company enforceable against the Company in accordance with
their terms, except as enforceability may be limited by applicable
bankruptcy, insolvency, reorganization, moratorium or similar laws affecting
creditors' and contracting parties' rights generally and except as
enforceability may be subject to general principles of equity (regardless of
whether such enforceability is considered in a proceeding in equity or at
law).

                  3.3 NON-CONTRAVENTION. The execution and delivery of the
Agreements, the issuance and sale of the Shares to be sold by the Company
under the Agreements, the fulfillment of the terms of the Agreements and the
consummation of the transactions contemplated thereby will not (A) result in
conflict with or constitute a violation of, or default (with the passage of
time or otherwise) under, (i) any bond, debenture, note or other evidence of
indebtedness, or any lease, contract, indenture, mortgage, deed of trust,
loan agreement, joint venture or other agreement or instrument to which the
Company is a party or by which the Company or its respective properties are
bound, where such conflict, violation or default is reasonably expected to
result in a Material Adverse Effect, (ii) the certificate of incorporation,
by-laws or other organizational documents of the Company, or (iii) any law,
administrative

                                       2
<PAGE>

regulation, ordinance or order of any court or governmental agency,
arbitration panel or authority binding upon the Company or its respective
properties, where such conflict, violation or default is likely to result in
a Material Adverse Effect or (B) result in the creation or imposition of any
lien, encumbrance, claim, security interest or restriction whatsoever upon
any of the material properties or assets of the Company or an acceleration of
indebtedness pursuant to any obligation, agreement or condition contained in
any material bond, debenture, note or any other evidence of indebtedness or
any material indenture, mortgage, deed of trust or any other agreement or
instrument to which the Company is a party or by which it is bound or to
which any of the property or assets of the Company is subject. No consent,
approval, authorization or other order of, or registration, qualification or
filing with, any regulatory body, administrative agency, or other
governmental body in the United States is required for the execution and
delivery of the Agreements by the Company and the valid issuance or sale of
the Shares by the Company pursuant to the Agreements, other than such as have
been made or obtained, and except for any filings required to be made under
federal or state securities laws.

                  3.4 CAPITALIZATION. The outstanding capital stock of the
Company as of September 30, 2000 is as described in the Company's Quarterly
Report on Form 10-Q for the quarter ended September 30, 2000. The Company has
not issued any capital stock since September 30, 2000 other than pursuant to
(i) the exercise of employee stock options under the stock option plans
disclosed in the SEC Reports, (ii) the exercise of rights under the Company's
Employee Stock Purchase Plan disclosed in the SEC Reports and (iii) 110,000
shares of restricted stock issued to the Company's Vice President, Sales and
Marketing. The Shares to be sold pursuant to the Agreements have been duly
authorized, and when issued and paid for in accordance with the terms of the
Agreements, will be duly and validly issued, fully paid and nonassessable.
The outstanding shares of capital stock of the Company have been duly and
validly issued and are fully paid and nonassessable, have been issued in
compliance with the registration requirements of federal and state securities
laws, and were not issued in violation of any preemptive rights or similar
rights to subscribe for or purchase securities. Except for options issued
under the Company's stock option plans, warrants outstanding as described in
the SEC Reports and rights under the Company's Employee Stock Purchase Plan
or Rights Agreement with Wells Fargo Bank Minnesota (formerly Norwest Bank
Minnesota) as Rights Agent, there are no outstanding rights (including,
without limitation, preemptive rights), warrants or options to acquire, or
instruments convertible into or exchangeable for, any unissued shares of
capital stock or other equity interest in the Company, or any contract,
commitment, agreement, understanding or arrangement of any kind, in either
case to which the Company is a party and providing for the issuance or sale
of any capital stock of the Company, any such convertible or exchangeable
securities or any such rights, warrants or options. Without limiting the
foregoing, no preemptive right, co-sale right, registration right, right of
first refusal or other similar right exists with respect to the issuance and
sale of the Shares, except as provided in the Agreements. There are no
stockholders agreements, voting agreements or other similar agreements with
respect to the Common Stock to which the Company is a party.

                  3.5 LEGAL PROCEEDINGS. There is no material legal or
governmental proceeding pending, or to the knowledge of the Company,
threatened, to which the Company is a party or of which the business or
property of the Company is subject. The Company is not a party to the
provisions of any injunction, judgment, decree or order of any court,
regulatory body, administrative agency or other government body which is
material to the business or operation of the Company.

                  3.6 NO VIOLATIONS. The Company is not in violation of its
certificate of incorporation, bylaws or other organizational documents, or in
violation of any law, administrative regulation, ordinance or order of any
court or governmental agency, arbitration panel or authority applicable to
the Company, which violation, individually or in the aggregate, is reasonably
likely to have a Material Adverse Effect, nor is the Company in default (and
there exists no condition which, with the

                                       3
<PAGE>

passage of time or otherwise, would constitute a default) in the performance
of any bond, debenture, note or any other evidence of indebtedness or any
indenture, mortgage, deed of trust or any other material agreement or
instrument to which the Company is a party or by which the Company is bound
or by which the property of the Company is bound, which default is reasonably
likely to have a Material Adverse Effect.

                  3.7 GOVERNMENTAL PERMITS, ETC. The Company has all
necessary franchises, licenses, certificates and other authorizations from
any foreign, federal, state or local government or governmental agency,
department or body that are currently necessary for the operation of the
business of the Company as currently conducted, except where the failure to
currently possess such franchises, licenses, certificates and other
authorizations is not reasonably be expected to have a Material Adverse
Effect.

                  3.8      INTELLECTUAL PROPERTY.

                           (a) Except for matters which are not reasonably
likely to have a Material Adverse Effect, (i) the Company has ownership of,
or a license or other legal right to use, all patents, copyrights, trade
secrets, trademarks, customer lists, designs, manufacturing or other
processes, computer software, systems, data compilation, research results or
other proprietary rights used in the business of the Company (collectively,
"INTELLECTUAL PROPERTY") and (ii) all of the Intellectual Property owned by
the Company consisting of patents, registered trademarks and registered
copyrights have been duly registered in, filed in or issued by the United
States Patent and Trademark Office, the United States Register of Copyrights
or the corresponding offices of other jurisdictions and have been maintained
and renewed in accordance with all applicable provisions of law and
administrative regulations in the United States and/or such other
jurisdictions.

                           (b) Except for matters which are not reasonably
likely to have a Material Adverse Effect, all material licenses or other
material agreements under which (i) the Company employs rights in
Intellectual Property, or (ii) the Company has granted rights to others in
Intellectual Property owned or licensed by the Company, are in full force and
effect and there is no default by the Company or any of its Subsidiaries
thereto.

                           (c) The Company believes that it has taken all
steps reasonably required in accordance with sound business practice and
business judgment to establish and preserve the Company's ownership of all
material Intellectual Property owned by the Company.

                           (d) Except for matters which are not reasonably
likely to have a Material Adverse Effect, to the knowledge of the Company,
(i) the present business, activities and products of the Company do not
infringe any intellectual property of any other person; (ii) the Company is
not making unauthorized use of any confidential information or trade secrets
of any person; and (iii) the activities of any of the employees on behalf of
the Company do not violate any agreements or arrangements related to
confidential information or trade secrets of persons other than the Company
or restricting any such employee's engagement in business activities of any
nature.

                           (e) No proceedings are pending, or to the
knowledge of the Company, threatened, which challenge the rights of the
Company in respect of the Company's right to the use of the Intellectual
Property, except for matters which are not reasonably likely to have a
Material Adverse Effect.

                                       4
<PAGE>

                  3.9 FINANCIAL STATEMENTS. The consolidated financial
statements of the Company and the related notes contained in the SEC Reports
present fairly, in accordance with generally accepted accounting principles,
the consolidated financial position of the Company as of the dates indicated,
and the results of its operations, cash flows and the changes in
stockholders' equity for the periods therein specified, subject, in the case
of unaudited financial statements for interim periods, to normal year-end
audit adjustments. Such consolidated financial statements (including the
related notes) have been prepared in accordance with generally accepted
accounting principles applied on a consistent basis throughout the periods
therein specified, except that unaudited financial statements may not contain
all footnotes required by generally accepted accounting principles.

                  3.10 NO MATERIAL ADVERSE CHANGE. Since September 30, 2000,
there has not been (i) a change that has had or is reasonably likely to have
a Material Adverse Effect, (ii) any obligation, direct or contingent, that is
material to the Company, incurred by the Company, except obligations incurred
in the ordinary course of business, (iii) any dividend or distribution of any
kind declared, paid or made on the capital stock of the Company, or (iv) any
loss or damage (whether or not insured) to the physical property of the
Company which has been sustained which has a Material Adverse Effect.

                  3.11 NASDAQ COMPLIANCE. The Company's Common Stock is
registered pursuant to Section 12(g) of the Securities Exchange Act of 1934,
as amended (the "EXCHANGE ACT"), and is listed on the Nasdaq National Market
(the "NASDAQ STOCK MARKET"), and the Company has taken no action designed to,
or which to its knowledge is likely to have the effect of, terminating the
registration of the Common Stock under the Exchange Act or delisting the
Common Stock from the Nasdaq Stock Market. The issuance of the Shares does
not require shareholder approval, including, without limitation, pursuant to
the Nasdaq Marketplace Rules.

                  3.12 REPORTING STATUS. The Company has timely made all
filings required under the Exchange Act during the 12 months preceding the
date of this Agreement, and all of those documents complied in all material
respects with the SEC's requirements as of their respective filing dates, and
the information contained therein as of the respective dates thereof did not
contain an untrue statement of a material fact or omit to state a material
fact required to be stated therein or necessary to make the statements
therein in light of the circumstances under which they were made not
misleading. The Company is currently eligible to register the resale of
Common Stock in a secondary offering on a registration statement on Form S-3
under the Securities Act of 1933, as amended (the "SECURITIES ACT").

                  3.13 NO MANIPULATION OF STOCK. The Company has not taken
and will not, in violation of applicable law, take any action outside the
ordinary course of business designed to or that might reasonably be expected
to cause or result in unlawful manipulation of the price of the Common Stock
to facilitate the sale or resale of the Shares.

                  3.14 ACCOUNTANTS. Ernst & Young LLP, who expressed their
opinion with respect to the consolidated financial statements to be
incorporated by reference from the Company's Annual Report on Form 10-K for
the year ended December 31, 1999 into the Registration Statement (as defined
below) and the prospectus which forms a part thereof (the "Prospectus"), have
advised the Company that they are, and to the knowledge of the Company they
are, independent accountants as required by the Securities Act and the rules
and regulations promulgated thereunder (the "RULES AND REGULATIONS").

                  3.15 CONTRACTS. Except for matters which are not reasonably
likely to have a Material Adverse Effect, the contracts listed as exhibits to
the SEC Reports that are material to the Company, other than those contracts
that are substantially or fully performed or expired by their terms, are in
full force

                                       5
<PAGE>

and effect on the date hereof, and none of the Company nor, to the Company's
knowledge, any other party to such contracts is in breach of or default under
any of such contracts.

                  3.16 TAXES. Except for matters which are not reasonably
expected to have a Material Adverse Effect, the Company has filed all
necessary federal, state and foreign income and franchise tax returns and has
paid or accrued all taxes shown as due thereon, and the Company has no
knowledge of a tax deficiency which has been asserted or threatened against
the Company.

                  3.17 TRANSFER TAXES. On the Closing Date, all stock
transfer or other taxes (other than income taxes) which are required to be
paid in connection with the sale and transfer of the Shares hereunder will
be, or will have been, fully paid or provided for by the Company and the
Company will have complied with all laws imposing such taxes.

                  3.18 INVESTMENT COMPANY. The Company is not an "investment
company" or an "affiliated person" of, or "promoter" or "principal
underwriter" for an investment company, within the meaning of the Investment
Company Act of 1940, as amended.

                  3.19 INSURANCE. The Company maintains insurance of the
types and in the amounts that the Company reasonably believes is adequate for
its business, including, but not limited to, insurance covering real and
personal property owned or leased by the Company against theft, damage,
destruction, acts of vandalism and all other risks customarily insured
against by similarly situated companies, all of which insurance is in full
force and effect.

                  3.20 OFFERING MATERIALS. The Company has not in the past
nor will it hereafter take any action to sell, offer for sale or solicit
offers to buy any securities of the Company which would bring the offer or
sale of the Shares as contemplated by this Agreement within the provisions of
Section 5 of the Securities Act.

                  3.21 LISTING. The Company shall comply with all
requirements of the NASD with respect to the issuance of the Shares and the
listing thereof on the Nasdaq Stock Market prior to issuance.

                  3.22 RELATED PARTY TRANSACTIONS. Other than the repayment
of loan proceeds to Medtronic, Inc. in February 2001, the issuance of 110,000
shares of restricted stock to the Company's Vice President, Sales and
Marketing, and the execution of employment and change in control agreements
with certain officers of the Company, no transaction has occurred between or
among the Company and its affiliates, officers or directors or any affiliate
or affiliates of any such officer or director that with the passage of time
will be required to be disclosed pursuant to Section 13, 14 or 15(d) of the
Exchange Act.

                  3.23 BOOKS AND RECORDS. The books, records and accounts of
the Company accurately and fairly reflect, in reasonable detail, the
transactions in, and dispositions of, the assets of, and the operations of,
the Company. The Company maintains a system of internal accounting controls
sufficient to provide reasonable assurances that (i) transactions are
executed in accordance with management's general or specific authorizations,
(ii) transactions are recorded as necessary to permit preparation of
financial statements in accordance with generally accepted accounting
principles and to maintain asset accountability, (iii) access to assets is
permitted only in accordance with management's general or specific
authorization and (iv) the recorded accountability for assets is compared
with the existing assets at reasonable intervals and appropriate action is
taken with respect to any differences.

                  3.24 FOREIGN CORRUPT PRACTICES ACT. Neither the Company nor
any of the Company's officers, employees, agents or any other person acting
on behalf of, at the direction

                                       6
<PAGE>

of, or for the benefit of the Company has, directly or indirectly, (i) used
any corporate funds for unlawful contributions, gifts, entertainment, or
other unlawful expenses relating to political activity, (ii) made any
unlawful contribution to any candidate for foreign or domestic office, or to
any foreign or domestic government officials or employees or other person
charged with similar public or quasi-public duties, other than payments
required or permitted by the laws of the United States or any jurisdiction
thereof or to foreign or domestic political parties or campaigns from
corporate funds, or failed to disclose fully any contribution in violation of
law, (iii) violated any provision of the Foreign Corrupt Practices Act of
1977, as amended, or (iv) made any other unlawful payment which, if not given
in the past or if not continued in the future would have a Material Adverse
Effect.

         4.       REPRESENTATIONS, WARRANTIES AND COVENANTS OF THE INVESTOR.

                  4.1 INVESTOR KNOWLEDGE AND STATUS. The Investor represents
and warrants to, and covenants with, the Company that: (i) the Investor is an
"accredited investor" as defined in Regulation D under the Securities Act and
has requested, received, reviewed and considered all information it deemed
relevant in making an informed decision to purchase the Shares; (ii) the
Investor understands that the Shares are "restricted securities" and have not
been registered under the Securities Act and is acquiring the number of
Shares set forth on the Signature Page hereto in the ordinary course of its
business and for its own account for investment only, has no present
intention of distributing any of such Shares and has no arrangement or
understanding with any other persons regarding the distribution of such
Shares (this representation and warranty not limiting the Investor's right to
sell Shares pursuant to the Registration Statement or otherwise, or other
than with respect to any claim arising out of a breach of this representation
and warranty, the Investor's right to indemnification under Section 6.3);
(iii) the Investor will not, directly or indirectly, offer, sell, pledge,
transfer or otherwise dispose of (or solicit any offers to buy, purchase or
otherwise acquire or take a pledge of) any of the Shares except in compliance
with the Securities Act, applicable state securities laws and the respective
rules and regulations promulgated thereunder; (iv) the Investor has answered
all questions on the Signature Page hereto and the Investor Questionnaire
attached hereto as Exhibit B for use in preparation of the Registration
Statement and the answers thereto are true and correct as of the date hereof
and will be true and correct as of the Closing Date; (v) the Investor will
notify the Company promptly of any change in any of such information until
such time as the Investor has sold all of its Shares or until the Company is
no longer required to keep the Registration Statement effective; and (vi) the
Investor has, in connection with its decision to purchase the number of
Shares set forth on the signature page hereto, relied only upon the
representations and warranties of the Company contained herein. Investor
understands that the issuance of the Shares to the Investor has not been
registered under the Securities Act, or registered or qualified under any
state securities law in reliance on specific exemptions therefrom, which
exemptions may depend upon, among other things, the bona fide nature of the
Investor's investment intent as expressed herein. The Placement Agent is not
authorized to make any representation or use any information in connection
with the placement, purchase and sale of the Shares, and no person is
authorized to provide any representation which is inconsistent or in addition
to those in the SEC Reports. The Investor acknowledges that it has not
received or relied on any such representations.

                  4.2 INTERNATIONAL ACTIONS. The Investor acknowledges,
represents and agrees that no action has been or will be taken in any
jurisdiction outside the United States by the Company or the Placement Agent
that would permit an offering of the Shares, or possession or distribution of
offering materials in connection with the issue of the Shares, in any
jurisdiction outside the United States. If the Investor is located outside
the United States, it has or will take all actions necessary for the sale of
the Shares to comply with all applicable laws and regulations in each foreign
jurisdiction in which it

                                       7
<PAGE>

purchases, offers, sells or delivers Shares or has in its possession or
distributes any offering material, in all cases at its own expense.

                  4.3 REGISTRATION REQUIRED. The Investor hereby covenants
with the Company not to make any sale of the Shares without complying with
the provisions of this Agreement, including Section 6.2 hereof, and without
effectively causing the prospectus delivery requirement under the Securities
Act to be satisfied (unless the Investor is selling such Shares in a
transaction not subject to the prospectus delivery requirement), and the
Investor acknowledges that the certificates evidencing the Shares will be
imprinted with a legend that prohibits their transfer except in accordance
therewith. The Investor acknowledges that as set forth in, and subject to the
provisions of, Section 6.2, there may occasionally be times when the Company,
based on the advice of its counsel, determines that it must suspend the use
of the Prospectus forming a part of the Registration Statement until such
time as an amendment to the Registration Statement has been filed by the
Company and declared effective by the SEC or until the Company has amended or
supplemented such Prospectus.

                  4.4 POWER AND AUTHORITY. The Investor further represents
and warrants to, and covenants with, the Company that (i) the Investor has
full right, power, authority and capacity to enter into this Agreement and to
consummate the transactions contemplated hereby and has taken all necessary
action to authorize the execution, delivery and performance of this
Agreement, and (ii) this Agreement constitutes a valid and binding obligation
of the Investor enforceable against the Investor in accordance with its
terms, except as enforceability may be limited by applicable bankruptcy,
insolvency, reorganization, moratorium or similar laws affecting creditors'
and contracting parties' rights generally and except as enforceability may be
subject to general principles of equity (regardless of whether such
enforceability is considered in a proceeding in equity or at law) and except
as the indemnification agreements of the Investors herein may be legally
unenforceable.

                  4.5 NO DISPOSITIONS. Except with the prior written consent
of the Company, the Investor will not, prior to the effectiveness of the
Registration Statement, or, if earlier, 60 days from the Closing Date, sell,
offer to sell, solicit offers to buy, dispose of, loan, pledge or grant any
right with respect to (collectively, a "DISPOSITION"), the Common Stock of
the Company, nor will Investor engage in any hedging or other transaction
which is designed to or could reasonably be expected to lead to or result in
a Disposition of Common Stock of the Company by the Investor or any other
person or entity. Such prohibited hedging or other transactions would
include, without limitation, effecting any short sale or having in effect any
short position (whether or not such sale or position is against the box and
regardless of when such position was entered into) or any purchase, sale or
grant of any right (including, without limitation, any put or call option)
with respect to the Common Stock of the Company.

                  4.6 NO TAX OR LEGAL ADVICE. The Investor understands that
nothing in this Agreement, or any other materials presented to the Investor
in connection with the purchase and sale of the Shares constitutes legal, tax
or investment advice. The Investor has consulted such legal, tax and
investment advisors as it, in its sole discretion, has deemed necessary or
appropriate in connection with its purchase of Shares.

         5. SURVIVAL OF REPRESENTATIONS, WARRANTIES AND AGREEMENTS.
Notwithstanding any investigation made by any party to this Agreement or by
the Placement Agent, all covenants, agreements, representations and
warranties made by the Company and the Investor herein shall survive the
execution of this Agreement, the delivery to the Investor of the Shares being
purchased and the payment therefor.

                                       8

<PAGE>

                  6. REGISTRATION OF THE SHARES; COMPLIANCE WITH THE
SECURITIES ACT.

                  6.1 REGISTRATION PROCEDURES AND EXPENSES. The Company shall:

                           (a) subject to receipt of necessary information
from the Investors, prepare and file with the SEC, as soon as practicable,
but in no event later than five (5) business days after the Closing Date, a
registration statement on Form S-3 (the "REGISTRATION STATEMENT") to enable
the resale of the Shares by the Investors from time to time through the
automated quotation system of the Nasdaq Stock Market or in
privately-negotiated transactions;

                           (b) use its best efforts, subject to receipt of
necessary information from the Investors, to cause the Registration Statement
to become effective as soon as practicable, but in no event later than sixty
(60) days after the Registration Statement is filed by the Company. If the
Registration Statement has not been declared effective by the SEC on or
before the date that is 90 days after the Closing Date, the Company shall, on
the 91st day after the Closing Date and each 30th day thereafter, issue to
the Investor .01 additional shares of Common Stock (which shall be deemed to
be Shares) for every Share purchased in the Offering until the Registration
Statement is declared effective by the SEC (rounded up to the nearest Share
after aggregating all Shares held by the Investor);

                           (c) use its best efforts to prepare and file with
the SEC such amendments and supplements to the Registration Statement and the
Prospectus used in connection therewith as may be necessary to keep the
Registration Statement current and effective for a period not exceeding, with
respect to each Investor's Shares purchased hereunder, the earlier of (i) the
second anniversary of the Closing Date, (ii) the date on which the Investor
may sell all Shares then held by the Investor without restriction by the
volume limitations of Rule 144(e) of the Securities Act or (iii) such time as
all Shares purchased by such Investor in this Offering have been sold
pursuant to a registration statement, and to notify each Investor promptly
upon the Registration Statement and each post-effective amendment thereto,
being declared effective by the SEC;

                           (d) furnish to the Investor with respect to the
Shares registered under the Registration Statement such number of copies of
the Registration Statement, Prospectuses (including supplemental
prospectuses) and preliminary versions of the Prospectus filed with the
Securities Exchange Commission ("PRELIMINARY PROSPECTUSES") in conformity
with the requirements of the Securities Act and such other documents as the
Investor may reasonably request, in order to facilitate the public sale or
other disposition of all or any of the Shares by the Investor, provided,
however, that unless waived by the Company in writing, the obligation of the
Company to deliver copies of Prospectuses or Preliminary Prospectuses to the
Investor shall be subject to the receipt by the Company of reasonable
assurances from the Investor that the Investor will comply with the
applicable provisions of the Securities Act and of such other securities or
blue sky laws as may be applicable in connection with any use of such
Prospectuses or Preliminary Prospectuses;

                           (e) file documents required of the Company for
normal blue sky clearance in all states requiring blue sky clearance;
provided, however, that the Company shall not be required to qualify to do
business or consent to service of process in any jurisdiction in which it is
not now so qualified or has not so consented;

                           (f) bear all expenses (other than underwriting
discounts and commissions, if any) in connection with the procedures in
paragraph (a) through (e) of this Section 6.1 (including reasonable fees and
expenses of one counsel for Investors) and the registration of the Shares
pursuant to the Registration Statement; and

                                       9
<PAGE>

                           (g) advise the Investors, promptly after it shall
receive notice or obtain knowledge of the issuance of any stop order by the
SEC delaying or suspending the effectiveness of the Registration Statement or
of the initiation of any proceeding for that purpose; and it will promptly
use its commercially reasonable efforts to prevent the issuance of any stop
order or to obtain its withdrawal at the earliest possible moment if such
stop order should be issued.

         With a view to making available to the Investor the benefits of Rule
144 (or its successor rule) and any other rule or regulation of the SEC that
may at any time permit the Investor to sell Shares to the public without
registration, the Company covenants and agrees to: (i) make and keep public
information available, as those terms are understood and defined in Rule 144,
until the earlier of (A) such date as all of the Investor's Shares may be
resold pursuant to Rule 144(k) or any other rule of similar effect or (B)
such date as all of the Investor's Shares shall have been resold; (ii) file
with the SEC in a timely manner all reports and other documents required of
the Company under the Securities Act and under the Exchange Act; and (iii)
furnish to the Investor upon request, as long as the Investor owns any
Shares, (A) a written statement by the Company that it has complied with the
reporting requirements of the Securities Act and the Exchange Act, (B) a copy
of the Company's most recent Annual Report on Form 10-K or Quarterly Report
on Form 10-Q, and (C) such other information as may be reasonably requested
in order to avail the Investor of any rule or regulation of the SEC that
permits the selling of any such Shares without registration.

         It shall be a condition precedent to the obligations of the Company
to take any action pursuant to this Section 6.1 that the Investor shall
furnish to the Company such information regarding itself, the Shares to be
sold by Investor, and the intended method of disposition of such securities
as shall be required to effect the registration of the Shares.

         The Company understands that the Investor disclaims being an
underwriter, but the Investor being deemed an underwriter by the SEC shall
not relieve the Company of any obligations it has hereunder.

                  6.2 TRANSFER OF SHARES AFTER REGISTRATION; SUSPENSION.

                           (a) The Investor agrees that it will not effect
any Disposition of the Shares or its right to purchase the Shares that would
constitute a sale within the meaning of the Securities Act other than
transactions exempt from the registration requirements of the Securities Act,
except as contemplated in the Registration Statement referred to in Section
6.1 and as described below, and that it will promptly notify the Company of
any changes in the information set forth in the Registration Statement
regarding the Investor or its plan of distribution.

                           (b) Except in the event that paragraph (c) below
applies, the Company shall: (i) if deemed necessary by the Company, prepare
and file from time to time with the SEC a post-effective amendment to the
Registration Statement or a supplement to the related Prospectus or a
supplement or amendment to any document incorporated therein by reference or
file any other required document so that such Registration Statement will not
contain an untrue statement of a material fact or omit to state a material
fact required to be stated therein or necessary to make the statements
therein not misleading, and so that, as thereafter delivered to purchasers of
the Shares being sold thereunder, such Prospectus will not contain an untrue
statement of a material fact or omit to state a material fact required to be
stated therein or necessary to make the statements therein, in light of the
circumstances under which they were made, not misleading; (ii) provide the
Investor copies of any documents filed pursuant to Section 6.2(b)(i); and
(iii) upon request, inform each Investor who so requests that the Company has
complied with its obligations in Section 6.2(b)(i) (or that, if the Company
has filed a post-effective amendment to the

                                       10
<PAGE>

Registration Statement which has not yet been declared effective, the Company
will notify the Investor to that effect, will use its reasonable efforts to
secure the effectiveness of such post-effective amendment as promptly as
possible and will promptly notify the Investor pursuant to Section 6.2(b)(i)
hereof when the amendment has become effective).

                           (c) Subject to paragraph (d) below, in the event:
(i) of any request by the SEC or any other federal or state governmental
authority during the period of effectiveness of the Registration Statement
for amendments or supplements to a Registration Statement or related
Prospectus or for additional information; (ii) of the issuance by the SEC or
any other federal or state governmental authority of any stop order
suspending the effectiveness of a Registration Statement or the initiation of
any proceedings for that purpose; (iii) of the receipt by the Company of any
notification with respect to the suspension of the qualification or exemption
from qualification of any of the Shares for sale in any jurisdiction or the
initiation of any proceeding for such purpose; or (iv) of any event or
circumstance which necessitates the making of any changes in the Registration
Statement or Prospectus, or any document incorporated or deemed to be
incorporated therein by reference, so that, in the case of the Registration
Statement, it will not contain any untrue statement of a material fact or any
omission to state a material fact required to be stated therein or necessary
to make the statements therein not misleading, and that in the case of the
Prospectus, it will not contain any untrue statement of a material fact or
any omission to state a material fact required to be stated therein or
necessary to make the statements therein, in the light of the circumstances
under which they were made, not misleading; then the Company shall promptly
deliver a certificate in writing to the Investor (the "SUSPENSION NOTICE") to
the effect of the foregoing and, upon receipt of such Suspension Notice, the
Investor will refrain from selling any Shares pursuant to the Registration
Statement (a "SUSPENSION") until the Investor's receipt of copies of a
supplemented or amended Prospectus prepared and filed by the Company, or
until it is advised in writing by the Company that the current Prospectus may
be used, and has received copies of any additional or supplemental filings
that are incorporated or deemed incorporated by reference in any such
Prospectus. In the event of any Suspension, the Company will use its
reasonable best efforts to cause the use of the Prospectus so suspended to be
resumed as soon as reasonably practicable after delivery of a Suspension
Notice to the Investors. In addition to and without limiting any other
remedies (including, without limitation, at law or at equity) available to
the Investor, the Investor shall be entitled to specific performance in the
event that the Company fails to comply with the provisions of this Section
6.2(c).

                           (d) Notwithstanding the foregoing paragraphs of
this Section 6.2, the Company shall use its best efforts to ensure that the
Investor shall not be prohibited from selling Shares under the Registration
Statement as a result of Suspensions on more than one occasion of not more
than 30 days in any twelve month period. If a Suspension is in effect for
more than 60 days (consecutive or non-consecutive) in any twelve-month
period, the Company shall, on the 61st day of the Suspension and each 30th
day thereafter, issue to the Investor .01 shares of Common Stock (which shall
be deemed to be Shares) for every Share purchased in the Offering until the
Suspension is lifted.

                           (e) Provided that a Suspension is not then in
effect the Investor may sell Shares under the Registration Statement,
provided that it arranges for delivery of a current Prospectus to the
transferee of such Shares. Upon receipt of a request therefor, the Company
will provide an adequate number of current Prospectuses to the Investor and
to any other parties requiring such Prospectuses.

                           (f) In the event of a sale of Shares by the
Investor, unless such requirement is waived by the Company in writing, the
Investor must also deliver to the Company's transfer agent, with a copy to
the Company, a Certificate of Subsequent Sale substantially in the form
attached hereto as Exhibit C, so that the shares may be properly transferred.

                                       11
<PAGE>

                  6.3 INDEMNIFICATION. For the purpose of this Section 6.3:

                      (a) the term "SELLING STOCKHOLDER" shall include
the Investor and each person, if any, who controls the Investor within the
meaning of Section 15 of the Securities Act or Section 20 of the Exchange Act;

                      (b) the term "REGISTRATION STATEMENT" shall
include any final Prospectus, exhibit, supplement or amendment included in or
relating to, and any document incorporated by reference in, the Registration
Statement (or deemed to be a part thereof) referred to in Section 6.1; and

                      (c) the term "UNTRUE STATEMENT" shall include any
untrue statement or alleged untrue statement, or any omission or alleged
omission to state in the Registration Statement a material fact required to
be stated therein or necessary to make the statements therein, in the light
of the circumstances under which they were made, not misleading.

                      (d)

                          (i) The Company agrees to indemnify and hold
harmless each Selling Stockholder from and against any losses, claims,
damages or liabilities to which such Selling Stockholder may become subject
(under the Securities Act or otherwise) insofar as such losses, claims,
damages or liabilities (or actions or proceedings in respect thereof) arise
out of, or are based upon (i) any untrue statement of a material fact
contained in the Registration Statement, (ii) any inaccuracy in the
representations and warranties of the Company contained in the Agreement or
the failure of the Company to perform its obligations hereunder or (iii) any
failure by the Company to fulfill any undertaking included in the
Registration Statement, and the Company will reimburse such Selling
Stockholder for any reasonable legal or other expenses reasonably incurred in
investigating, defending or preparing to defend any such action, proceeding
or claim, provided, however, that the Company shall not be liable in any such
case to the extent that such loss, claim, damage or liability arises out of,
or is based upon, an untrue statement made in such Registration Statement in
reliance upon and in conformity with written information furnished to the
Company by or on behalf of such Selling Stockholder specifically for use in
preparation of the Registration Statement or the failure of such Selling
Stockholder to comply with its covenants and agreements contained in Sections
4.1, 4.2, 4.3 or 6.2 hereof or any statement or omission in any Prospectus
that is corrected in any subsequent Prospectus that was delivered to the
Investor prior to the pertinent sale or sales by the Investor.

                          (ii) The Investor agrees to indemnify and hold
harmless the Company (and each person, if any, who controls the Company
within the meaning of Section 15 of the Securities Act, each officer of the
Company who signs the Registration Statement and each director of the
Company) from and against any losses, claims, damages or liabilities to which
the Company (or any such officer, director or controlling person) may become
subject (under the Securities Act or otherwise), insofar as such losses,
claims, damages or liabilities (or actions or proceedings in respect thereof)
arise out of, or are based upon, (i) any failure to comply with the covenants
and agreements contained in Section 4.1, 4.2, 4.3 or 6.2 hereof, or (ii) any
untrue statement of a material fact contained in the Registration Statement
if such untrue statement was made in reliance upon and in conformity with
written information furnished by or on behalf of the Investor specifically
for use in preparation of the Registration Statement, and the Investor will
reimburse the Company (or such officer, director or controlling person), as
the case may be, for any legal or other expenses reasonably incurred in
investigating, defending or preparing to defend any such action, proceeding
or claim. The obligation to indemnify shall be limited to the net amount of
the proceeds received by the Investor from the sale of the Shares pursuant to
the Registration Statement.

                                       12
<PAGE>

                          (iii) Promptly after receipt by any indemnified
person of a notice of a claim or the beginning of any action in respect of
which indemnity is to be sought against an indemnifying person pursuant to
this Section 6.3, such indemnified person shall notify the indemnifying
person in writing of such claim or of the commencement of such action, but
the omission to so notify the indemnifying party will not relieve it from any
liability which it may have to any indemnified party under this Section 6.3
(except to the extent that such omission materially and adversely affects the
indemnifying party's ability to defend such action) or from any liability
otherwise than under this Section 6.3. Subject to the provisions hereinafter
stated, in case any such action shall be brought against an indemnified
person, the indemnifying person shall be entitled to participate therein,
and, to the extent that it shall elect by written notice delivered to the
indemnified party promptly after receiving the aforesaid notice from such
indemnified party, shall be entitled to assume the defense thereof, with
counsel reasonably satisfactory to such indemnified person. After notice from
the indemnifying person to such indemnified person of its election to assume
the defense thereof (unless it has failed to assume the defense thereof and
appoint counsel reasonably satisfactory to the indemnified party), such
indemnifying person shall not be liable to such indemnified person for any
legal expenses subsequently incurred by such indemnified person in connection
with the defense thereof, provided, however, that if there exists or shall
exist a conflict of interest that would make it inappropriate, in the
reasonable opinion of counsel to the indemnified person, for the same counsel
to represent both the indemnified person and such indemnifying person or any
affiliate or associate thereof, the indemnified person shall be entitled to
retain its own counsel at the expense of such indemnifying person; provided,
however, that no indemnifying person shall be responsible for the fees and
expenses of more than one separate counsel (together with appropriate local
counsel) for all indemnified parties. In no event shall any indemnifying
person be liable in respect of any amounts paid in settlement of any action
unless the indemnifying person shall have approved the terms of such
settlement; provided that such consent shall not be unreasonably withheld. No
indemnifying person shall, without the prior written consent of the
indemnified person, effect any settlement of any pending or threatened
proceeding in respect of which any indemnified person is or could reasonably
have been a party and indemnification could have been sought hereunder by
such indemnified person, unless such settlement includes an unconditional
release of such indemnified person from all liability on claims that are the
subject matter of such proceeding.

                          (iv) If the indemnification provided for in this
Section 6.3 is unavailable to or insufficient to hold harmless an indemnified
party under subsection (d)(i) or (d)(ii) above in respect of any losses,
claims, damages or liabilities (or actions or proceedings in respect thereof)
referred to therein, then each indemnifying party shall contribute to the
amount paid or payable by such indemnified party as a result of such losses,
claims, damages or liabilities (or actions in respect thereof) in such
proportion as is appropriate to reflect the relative fault of the Company on
the one hand and the Investor on the other in connection with the statements
or omissions or other matters which resulted in such losses, claims, damages
or liabilities (or actions in respect thereof), as well as any other relevant
equitable considerations. The relative fault shall be determined by reference
to, among other things, in the case of an untrue statement, whether the
untrue statement relates to information supplied by the Company on the one
hand or the Investor on the other and the parties' relative intent,
knowledge, access to information and opportunity to correct or prevent such
untrue statement. The Company and the Investor agree that it would not be
just and equitable if contribution pursuant to this subsection (d) were
determined by pro rata allocation (even if the Investors were treated as one
entity for such purpose) or by any other method of allocation which does not
take into account the equitable considerations referred to above in this
subsection (d). The amount paid or payable by an indemnified party as a
result of the losses, claims, damages or liabilities (or actions in respect
thereof) referred to above in this subsection (d) shall be deemed to include
any legal or other expenses reasonably incurred by such indemnified party in
connection with investigating or defending any such action or claim.
Notwithstanding the provisions of this subsection (d), the Investor shall not
be required to contribute any amount in excess of the amount by

                                       13
<PAGE>

which the gross amount received by the Investor from the sale of the Shares
to which such loss relates exceeds the amount of any damages which the
Investor has otherwise been required to pay by reason of such untrue
statement. No person guilty of fraudulent misrepresentation (within the
meaning of Section 11(f) of the Securities Act) shall be entitled to
contribution from any person who was not guilty of such fraudulent
misrepresentation. The Investors' obligations in this subsection to
contribute are several in proportion to their sales of Shares to which such
loss relates and not joint.

                          (v) The parties to this Agreement hereby
acknowledge that they are sophisticated business persons who were represented
by counsel during the negotiations regarding the provisions hereof including,
without limitation, the provisions of this Section 6.3, and are fully
informed regarding said provisions. They further acknowledge that the
provisions of this Section 6.3 fairly allocate the risks in light of the
ability of the parties to investigate the Company and its business in order
to assure that adequate disclosure is made in the Registration Statement as
required by the Securities Act and the Exchange Act.

                  6.4 TERMINATION OF CONDITIONS AND OBLIGATIONS. The
conditions precedent imposed by Section 4 or this Section 6 upon the
transferability of the Shares shall cease and terminate as to any particular
number of the Shares when such Shares shall have been effectively registered
under the Securities Act and sold or otherwise disposed of in accordance with
the intended method of disposition set forth in the Registration Statement
covering such Shares or at such time as an opinion of counsel satisfactory to
the Company shall have been rendered to the effect that such conditions are
not necessary in order to comply with the Securities Act.

                  6.5 INFORMATION AVAILABLE. So long as the Registration
Statement is effective covering the resale of Shares owned by the Investor,
the Company will furnish (or to the extent such information is available
electronically through the Company's filings with the SEC, the Company will
make available) to the Investor:

                      (a) as soon as practicable after it is available, one
copy of (i) its Annual Report to Stockholders (which Annual Report shall
contain financial statements audited in accordance with generally accepted
accounting principles by a national firm of certified public accountants) and
(ii) if not included in substance in the Annual Report to Stockholders, its
Annual Report on Form 10-K (the foregoing, in each case, excluding exhibits);

                      (b) upon the reasonable request of the Investor, all
exhibits excluded by the parenthetical to subparagraph (a)(ii) of this
Section 6.5 as filed with the SEC and all other information that is made
available to stockholders; and

                      (c) upon the reasonable request of the Investor, an
adequate number of copies of the Prospectuses to supply to any other party
requiring such Prospectuses; and the Company, upon the reasonable request of
the Investor, will meet with the Investor or a representative thereof at the
Company's headquarters to discuss all information relevant for disclosure in
the Registration Statement covering the Shares and will otherwise reasonably
cooperate with the Investor conducting an investigation for the purpose of
reducing or eliminating the Investor's exposure to liability under the
Securities Act, including the reasonable production of information at the
Company's headquarters; provided, that the Company shall not be required to
disclose any confidential information to or meet at its headquarters with the
Investor until and unless the Investor shall have entered into a
confidentiality agreement in form and substance reasonably satisfactory to
the Company with the Company with respect thereto.

                                       14
<PAGE>

                  6.6 PUBLIC STATEMENTS. The Company will not issue any
public statement, press release or any other public disclosure listing
Investor as one of the purchasers of the Shares without Investor's prior
written consent, except as may be required by applicable law or rules of any
exchange on which the Company's securities are listed.

         7. NOTICES. All notices, requests, consents and other communications
hereunder shall be in writing, shall be mailed (A) if within domestic United
States by first-class registered or certified airmail, or nationally
recognized overnight express courier, postage prepaid, or by facsimile, or
(B) if delivered from outside the United States, by International Federal
Express (or comparable service) or facsimile, and shall be deemed given (i)
if delivered by first-class registered or certified mail domestic, three
business days after so mailed, (ii) if delivered by nationally recognized
overnight carrier, one (1) business day after so mailed, (iii) if delivered
by International Federal Express (or comparable service), two (2) business
days after so mailed, (iv) if delivered by facsimile, upon electric
confirmation of receipt and shall be delivered as addressed as follows:

                           (a)      if to the Company, to:

                                    Endocardial Solutions, Inc.
                                    1350 Energy Lane, Suite 110
                                    St. Paul, MN 55108
                                    Attention:   James Bullock
                                    Telephone:   (651) 644-5381
                                    Telecopy:    (651) 644-7897

                                    with a copy mailed to:

                                    Dorsey & Whitney LLP
                                    Pillsbury Center South
                                    220 South Sixth Street
                                    Minneapolis, MN 55402
                                    Attention:   Ken Cutler
                                    Telephone:   (612) 340-2740
                                    Telecopy:    (612) 340-8738

                           (b) if to the Investor, at its address on the
Signature Page hereto, or at such other address or addresses as may have been
furnished to the Company in writing.

                  8. CHANGES. This Agreement may not be modified or amended
except pursuant to an instrument in writing signed by the Company and the
Investor.

                  9. HEADINGS. The headings of the various sections of this
Agreement have been inserted for convenience of reference only and shall not
be deemed to be part of this Agreement.

                  10. SEVERABILITY. In case any provision contained in this
Agreement should be invalid, illegal or unenforceable in any respect, the
validity, legality and enforceability of the remaining provisions contained
herein shall not in any way be affected or impaired thereby.

                  11. GOVERNING LAW. This Agreement shall be governed by, and
construed in accordance with, the internal laws of the State of Minnesota,
without giving effect to the principles of conflicts of law.

                                       15
<PAGE>

         12. COUNTERPARTS. This Agreement may be executed in two or more
counterparts, each of which shall constitute an original, but all of which,
when taken together, shall constitute but one instrument, and shall become
effective when one or more counterparts have been signed by each party hereto
and delivered to the other parties.

         13. CONFIDENTIAL DISCLOSURE AGREEMENT. Notwithstanding any provision
of this Agreement to the contrary, any confidential disclosure agreement
previously executed by the Company and the Investor in connection with the
transactions contemplated by this Agreement shall remain in full force and
effect in accordance with its terms following the execution of this Agreement
and the consummation of the transactions contemplated hereby.

         14. LIMITATION OF LIABILITY. The name H&Q Healthcare Investors is
the designation of the Trustees for the time being under an Amended and
Restated Declaration of Trust dated April 21, 1987, as amended, and all
persons dealing with H&Q Healthcare Investors must look solely to the trust
property for the enforcement of any claim against H&Q Healthcare Investors,
as neither the Trustees, officers nor shareholders assume any personal
liability for the obligations entered into on behalf of H&Q Healthcare
Investors. The name H&Q Life Sciences Investors is the designation of the
Trustees for the time being under a Declaration of Trust dated February 20,
1992, as amended, and all persons dealing with H&Q Life Sciences Investors
must look solely to the trust property for the enforcement of any claims
against H&Q Life Sciences Investors, as neither the Trustees, officers nor
shareholders assume any personal liability for the obligations entered into
on behalf of H&Q Life Sciences Investors.

                                       16
<PAGE>
                                    EXHIBIT A

                           ENDOCARDIAL SOLUTIONS, INC.

                         STOCK CERTIFICATE QUESTIONNAIRE

         Pursuant to Section 4 of the Agreement, please provide us with the
following information:

1.        The exact name that your Shares are to be        ____________________
          registered in (this is the name that will appear
          on your stock certificate(s)).  You may use a
          nominee name if appropriate:

2.        The relationship between the Investor and the    ____________________
          registered holder listed in response to item 1
          above:

3.        The mailing address of the registered holder     ____________________
          listed in response to item 1 above:

4.        The Social Security Number or Tax                ____________________
          Identification Number of the registered holder
          listed in the response to item 1
          above:

                                       1

<PAGE>

                                    EXHIBIT B

                           ENDOCARDIAL SOLUTIONS, INC.

                             INVESTOR QUESTIONNAIRE

                (ALL INFORMATION WILL BE TREATED CONFIDENTIALLY)

To: Endocardial Solutions, Inc.,

         This Investor Questionnaire ("QUESTIONNAIRE") must be completed by
each potential investor in connection with the offer and sale of the shares
of the common stock, par value $.01 per share (the "SHARES"), of Endocardial
Solutions, Inc. (the "COMPANY"). The Shares are being offered and sold by the
Company without registration under the Securities Act of 1933, as amended
(the "SECURITIES ACT"), and the securities laws of certain states, in
reliance on the exemptions contained in Section 4 of the Securities Act and
on Regulation D promulgated thereunder and in reliance on similar exemptions
under applicable state laws. The Company must determine that a potential
investor meets certain suitability requirements before offering or selling
Shares to such investor. The purpose of this Questionnaire is to assure the
Company that each investor will meet the applicable suitability requirements.
The information supplied by you will be used in determining whether you meet
such criteria, and reliance upon the private offering exemption from
registration is based in part on the information herein supplied.

         This Questionnaire does not constitute an offer to sell or a
solicitation of an offer to buy any security. Your answers will be kept
strictly confidential. However, by signing this Questionnaire you will be
authorizing the Company to provide a completed copy of this Questionnaire to
such parties as the Company deems appropriate in order to ensure that the
offer and sale of the Shares will not result in a violation of the Securities
Act or the securities laws of any state and that you otherwise satisfy the
suitability standards applicable to purchasers of the Shares. All potential
investors must answer all applicable questions and complete, date and sign
this Questionnaire. Please print or type your responses and attach additional
sheets of paper if necessary to complete your answers to any item.

A.       BACKGROUND INFORMATION

Name: _________________________________________________________________________

Business Address: _____________________________________________________________
                               (Number and Street)

_______________________________________________________________________________
(City)                                 (State)                 (Zip Code)

Telephone Number:  (         ) ________________________________________________

Residence Address: ____________________________________________________________
                               (Number and Street)

_______________________________________________________________________________
(City)                                  (State)                 (Zip Code)

Telephone Number:  (         ) ________________________________________________

If an individual:

Age: _____ Citizenship: __________ Where registered to vote: __________________

If a corporation, partnership, limited liability company, trust or other entity:

Type of entity: _______________________________________________________________

State of formation: __________________  Date of formation: ____________________

Social Security or Taxpayer Identification No. ________________________________

                                       1
<PAGE>

Send all correspondence to (check one): __ Residence Address __ Business Address

B.       STATUS AS ACCREDITED INVESTOR

The undersigned is an "accredited investor" as such term is defined in
Regulation D under the Securities Act, as at the time of the sale of the
Shares the undersigned falls within one or more of the following categories
(Please initial one or more, as applicable):

_____ (1) a bank as defined in Section 3(a)(2) of the Securities Act, or a
savings and loan association or other institution as defined in Section
3(a)(5)(A) of the Securities Act whether acting in its individual or
fiduciary capacity; a broker or dealer registered pursuant to Section 15 of
the Securities Exchange Act of 1934; an insurance company as defined in
Section 2(13) of the Securities Act; an investment company registered under
the Investment Company Act of 1940 or a business development company as
defined in Section 2(a)(48) of that act; a Small Business Investment Company
licensed by the U.S. Small Business Administration under Section 301(c) or
(d) of the Small Business Investment Act of 1958; a plan established and
maintained by a state, its political subdivisions, or any agency or
instrumentality of a state or its political subdivisions for the benefit of
its employees, if such plan has total assets in excess of $5,000,000; an
employee benefit plan within the meaning of the Employee Retirement Income
Security Act of 1974 if the investment decision is made by a plan fiduciary,
as defined in Section 3(21) of such act, which is either a bank, savings and
loan association, insurance company, or registered investment adviser, or if
the employee benefit plan has total assets in excess of $5,000,000 or, if a
self-directed plan, with the investment decisions made solely by persons that
are accredited investors;(1)

_____ (2) a private business development company as defined in Section
202(a)(22) of the Investment Adviser Act of 1940;

_____ (3) an organization described in Section 501(c)(3) of the Internal
Revenue Code of 1986, as amended, corporation, Massachusetts or similar
business trust, or partnership, not formed for the specific purpose of
acquiring the Shares offered, with total assets in excess of $5,000,000;

_____ (4) a natural person whose individual net worth, or joint net worth
with that person's spouse, at the time of such person's purchase of the
Shares exceeds $1,000,000;

_____ (5) a natural person who had an individual income in excess of $200,000
in each of the two most recent years or joint income with that person's
spouse in excess of $300,000 in each of those years and has a reasonable
expectation of reaching the same income level in the current year;

_____ (6) a trust, with total assets in excess of $5,000,000, not formed for
the specific purpose of acquiring the Shares offered, whose purchase is
directed by a sophisticated person as described in Rule 506(b)(2)(ii) of
Regulation D; and

_____ (7) an entity in which all of the equity owners are accredited
investors (as defined above).

-------------------
(1) As used in this Questionnaire, the term "net worth"
means the excess of total assets over total liabilities. In computing net
worth for the purpose of subsection (4), the principal residence of the
investor must be valued at cost, including cost of improvements, or at
recently appraised value by an institutional lender making a secured loan,
net of encumbrances. In determining income, the investor should add to the
investor's adjusted gross income any amounts attributable to tax exempt
income received, losses claimed as a limited partner in any limited
partnership, deductions claimed for depreciation, contributions to an IRA or
KEOGH retirement plan, alimony payments, and any amount by which income from
long-term capital gains has been reduced in arriving at adjusted gross income.

                                       B-2
<PAGE>

C.       REPRESENTATIONS

The undersigned hereby represents and warrants to the Company as follows:

         1. Any purchase of the Shares would be solely for the account of the
undersigned and not for the account of any other person or with a view to any
resale, fractionalization, division, or distribution thereof.

         2. The information contained herein is complete and accurate and may
be relied upon by the Company, and the undersigned will notify the Company
immediately of any material change in any of such information occurring prior
to the closing, if any, with respect to the purchase of Shares by the
undersigned or any co-purchaser.

         3. There are no suits, pending litigation, or claims against the
undersigned that could materially affect the net worth of the undersigned as
reported in this Questionnaire.

         4. The undersigned acknowledges that there may occasionally be times
when the Company, based on the advice of its counsel, determines that it must
suspend the use of the Prospectus forming a part of the Registration
Statement (as such terms are defined in the Stock Purchase Agreement to which
this Questionnaire is attached) until such time as an amendment to the
Registration Statement has been filed by the Company and declared effective
by the Securities and Exchange Commission or until the Company has amended or
supplemented such Prospectus. The undersigned is aware that, in such event,
the Shares will not be subject to ready liquidation, and that any Shares
purchased by the undersigned would have to be held during such suspension.
The overall commitment of the undersigned to investments which are not
readily marketable is not excessive in view of the undersigned's net worth
and financial circumstances, and any purchase of the Shares will not cause
such commitment to become excessive. The undersigned is able to bear the
economic risk of an investment in the Shares.

         5. The undersigned has carefully considered the potential risks
relating to the Company and a purchase of the Shares, and fully understands
that the Shares are speculative investments which involve a high degree of
risk of loss of the undersigned's entire investment. Among others, the
undersigned has carefully considered each of the risks described under the
headings "Cautionary Statements" in the Company's Annual Report on Form 10-K
for the year ended December 31, 1999 and the Company's Quarterly Reports on
Form 10-Q for the quarters ended March 31, 2000, June 30, 2000 and September
30, 2000.

                                      B-3
<PAGE>

IN WITNESS WHEREOF, the undersigned has executed this Questionnaire this
_____ day of March, 2001, and declares under oath that it is truthful and
correct.

                                       Print Name

                                       By: ____________________________________
                                       Signature

                                       Title: _________________________________
                                              (required for any purchaser that
                                              is a corporation, partnership,
                                              trust or other entity)

                                      B-4
<PAGE>

                                    EXHIBIT C

                           ENDOCARDIAL SOLUTIONS, INC.
                         CERTIFICATE OF SUBSEQUENT SALE

Wells Fargo Bank Minnesota, N.A.

         RE:      Sale of Shares of Common Stock of Endocardial Solutions, Inc.
                  (the "Company") pursuant to the Company's Prospectus dated
                  _______________, 2001 (the "Prospectus")

Dear Sir/Madam:

         The undersigned hereby certifies, in connection with the sale of
shares of Common Stock of the Company included in the table of Selling
Stockholders in the Prospectus, that the undersigned has sold the Shares
pursuant to the Prospectus and in a manner described under the caption "Plan
of Distribution" in the Prospectus and that such sale complies with all
applicable securities laws, including, without limitation, the Prospectus
delivery requirements of the Securities Act of 1933, as amended.

     Selling Stockholder (the beneficial owner): ______________________________

     Record Holder (e.g., if held in name of nominee): ________________________

     Restricted Stock Certificate No.(s): _____________________________________

     Number of Shares Sold: ___________________________________________________

     Date of Sale: ____________________________________________________________

         In the event that you receive a stock certificate(s) representing
more shares of Common Stock than have been sold by the undersigned, then you
should return to the undersigned a newly issued certificate for such excess
shares in the name of the Record Holder and BEARING A RESTRICTIVE LEGEND.
Further, you should place a stop transfer on your records with regard to such
certificate.

Dated: ___________________             Very truly yours,

                                       By: ____________________________________

                                       Print Name: ____________________________

                                       Title: _________________________________

                                       1
<PAGE>

                                    EXHIBIT D

                              FORM OF LEGAL OPINION

                                 March ___, 2001

To:      The Investors in Common Stock of Endocardial Solutions, Inc.

Ladies and Gentlemen:

                  We have acted as counsel for Endocardial Solutions, Inc., a
Delaware corporation (the "Company"), in connection with the issuance of
__________ shares (the "Shares") of the Company's Common Stock, $.01 par
value per share, pursuant to those certain Stock Purchase Agreements, dated
as of March ___, 2001, including the exhibits thereto (collectively, the
"Agreement"), between the Company and the Investors named therein. This
opinion is being delivered to you pursuant to Section 2 of the Agreement.
Capitalized terms used herein are as defined in the Agreement unless
otherwise specifically provided herein.

                  We have examined such documents and have reviewed such
questions of law as we have considered necessary or appropriate for the
purpose of this opinion.

                  In rendering our opinion below, we have assumed the
authenticity of all documents submitted to us as originals, the genuineness
of all signatures, and the conformity to authentic originals of all documents
submitted to us as copies. We have also assumed the legal capacity for all
purposes relevant hereto of all parties to all relevant agreements other than
the Company. As to questions of fact material to our opinion, we have relied,
without independent verification, on the representations and warranties
contained in the Agreement and certificates of officers of the Company and
public officials.

                  Our opinions expressed below as to certain factual matters
are qualified as being limited "to our knowledge" or by other words to the
same or similar effect. Such words, as used herein, mean the information
known to Kenneth L. Cutler and Robert A. Kuhns, the attorneys in this firm
who have represented the Company in connection with the matters addressed
herein. In rendering such opinions, we have not conducted any independent
investigation or consulted with other attorneys in our firm with respect to
the matters covered by the Agreement. No inference as to our knowledge with
respect to such matters should be drawn from the fact of our representation
of the Company.

                  Based on the foregoing, we are of the opinion that:

                           1. The Company is a corporation duly incorporated,
                  validly existing and in good standing under the laws of the
                  State of Delaware, with the corporate power to conduct any
                  lawful business activity. The Company has the corporate power
                  to execute, deliver and perform the Agreement, including
                  without limitation, the issuance and sale of the Shares.

                           2. The Company is duly qualified to do business as a
                  foreign corporation in each U.S. jurisdiction in which the
                  character of the business conducted by it or the location of
                  the properties owned or leased by it makes such qualification
                  necessary,

                                        1
<PAGE>

                  except where the failure to be so qualified would not have a
                  material adverse effect on the financial position if the
                  Company.

                           3. The Agreement has been duly authorized by all
                  requisite corporate action, executed and delivered by the
                  Company. The Agreement constitutes the valid and binding
                  agreement of the Company enforceable in accordance with its
                  terms.

                           4. The Shares have been duly authorized and, upon
                  issuance, delivery and payment therefor as described in the
                  Agreement, will be validly issued, fully paid and
                  nonassessable.

                           5. As of the date hereof, the authorized capital
                  stock of the Company consists of 40,000,000 shares, $.01 par
                  value, of Common Stock and 10,000,000 shares, $.01 par value,
                  of undesignated Preferred Stock.

                           6. The execution, delivery and performance of the
                  Agreement and the issuance and sale of the Shares in
                  accordance with the Agreement will not: (a) violate or
                  conflict with, or result in a breach of or default under, the
                  Articles or by-laws of the Company, (b) violate or conflict
                  with, or constitute a default under, the provisions of any
                  material agreement (limited, with your consent, to agreements
                  filed with the Securities and Exchange Commission under the
                  Exchange Act and applicable rules and regulations) to which
                  the Company is a party, or (c) violate any law of the United
                  States or the Delaware General Corporation Law.

                           7. To our knowledge, no consent, approval,
                  authorization or order of, and no notice to or filing with,
                  any governmental agency or body or any court is required to be
                  obtained or made by the Company for the issue and sale of the
                  Shares pursuant to the Agreement, except such as have been
                  obtained or made and such as may be required under the federal
                  securities laws or the Blue Sky laws of the various states or
                  the bylaws and rules of the National Association of Securities
                  Dealers.

                           8. Assuming (a) the representations made by the
                  Investors in the Agreement are true and correct, and (b)
                  neither the Company, nor anyone acting on its behalf, engaged
                  in any form of general solicitation or general advertising in
                  connection with the offering and sale of the Shares, the
                  offer, sale, issuance and delivery of the Shares to the
                  Investors, in the manner contemplated by the Agreement, does
                  not need to be registered under the Securities Act.

                           9. The issuance of the Shares does not require
                  approval of the Company's stockholders pursuant to the Nasdaq
                  Marketplace Rules.

                           10. The Shares are "Covered Securities" pursuant to
                  the definition of that term in Section 18(b) of the Securities
                  Act.

                           11. At the time the SEC Reports were filed and in
                  connection with this transaction, we reviewed and had limited
                  telephone conversations with certain officers of the Company
                  regarding the contents of the SEC Reports. Although we are not
                  passing upon and have not independently checked or verified
                  the accuracy, completeness or fairness of the statements
                  contained in the SEC Reports, and our involvement in their
                  preparation was limited to the review and telephone
                  conversations set forth above, we

                                        2

<PAGE>

                  advise you that we did not, and do not have actual knowledge,
                  and no facts have come to our attention that have caused us to
                  believe as of the date of the Agreements or the date hereof,
                  that the SEC Reports (except as to the financial statements as
                  to which we do not advise you), when taken as a whole,
                  contained, at their time of filing, or contain as of the date
                  hereof an untrue statement of a material fact or omitted, at
                  their time of filing, or omit as of the date hereof to state a
                  material fact required to be stated therein or necessary to
                  make the statements therein, in the light of the circumstances
                  under which they were made, not misleading.

                  The opinions set forth above are subject to the following
                  qualifications and exceptions:

                           (a) We are admitted to practice law in the State of
                  Minnesota and our opinions expressed above are limited to the
                  laws of the State of Minnesota, the General Corporation Law of
                  the State of Delaware and the federal laws of the United
                  States of America.

                           (b) Our opinion in paragraph 3 above is subject to
                  the effect of any applicable bankruptcy, insolvency,
                  reorganization, moratorium or other similar laws of general
                  application affecting creditors' rights.

                           (c) Our opinion in paragraph 3 above is subject to
                  the effect of general principles of equity, including (without
                  limitation) concepts of materiality, reasonableness, good
                  faith, fair dealing and unconscionability, and other similar
                  doctrines affecting the enforceability of agreements generally
                  (regardless of whether considered in a proceeding in equity or
                  at law.).

                           (d) Our opinion in paragraph 3 above, insofar as it
                  relates to indemnification provisions, is subject to the
                  effect of federal and state securities laws and public policy
                  relating thereto.

                           (e) With respect to our opinion in paragraph 8 above,
                  we express no opinion as to any subsequent resale of any such
                  Shares.

                           (f) We express no opinion as to the compliance or the
                  effect of noncompliance by the Investors with any state or
                  federal laws or regulations applicable to the Investors in
                  connection with the transactions described in the Agreement.

                           (g) Minnesota Statutes Section 290.371, Subd. 4,
                  provides that any corporation required to file a Notice of
                  Business Activities Report does not have a cause of action
                  upon which it may bring suit under Minnesota law unless the
                  corporation has filed a Notice of Business Activities Report
                  and further provides that the use of the courts of the State
                  of Minnesota for all contracts executed and all causes of
                  action that arose before the end of any period for which a
                  corporation failed to file a required report is precluded.
                  Insofar as our opinion may relate to the valid, binding and
                  enforceable character of any agreement under Minnesota law or
                  in a Minnesota court, we have assumed that any party seeking
                  to enforce such agreement has at all times been, and will
                  continue at all times to be, exempt from the requirement of
                  filing a Notice of Business Activities Report or, if not
                  exempt, has duly filed, and will continue to duly file, all
                  Notice of Business Activities Reports

                                        3
<PAGE>

                  The opinions expressed herein are based on an analysis of
existing laws and court decisions and cover certain matters not directly
addressed by such authorities. The foregoing opinions are being furnished to
you solely for your benefit in connection with the transactions contemplated
by the Agreement and may not be relied upon by any other person without our
prior written consent. We disclaim any obligation to update this opinion
letter for events occurring or coming to our attention, or any changes in the
law taking effect, after the date hereof.

                                       Very truly yours,

                                       4<PAGE>

                                                                   Exhibit 10.30
                             STOCK PURCHASE WARRANT

                          TO SUBSCRIBE FOR AND PURCHASE
                                 COMMON STOCK OF

                           ENDOCARDIAL SOLUTIONS, INC.

                  THIS CERTIFIES THAT, for value received, U.S. Bancorp Piper
Jaffray, or registered assigns, (herein called "Purchaser"), is entitled to
subscribe for and purchase from Endocardial Solutions, Inc. (herein called
the "Company"), a corporation organized and existing under the laws of the
State of Delaware, at the price specified below (subject to adjustment as
noted below) at any time after the date hereof to, and including December 31,
2001 (the "Expiration Date"), One Hundred Twenty-Two Thousand Four Hundred
Fifty (122,450) fully paid and nonassessable shares of common stock (herein
the "Common Stock") (subject to adjustment as noted below). This Warrant has
been issued pursuant to an Engagement Agreement dated as of March 3, 2001
(the "Agreement") between the Purchaser and the Company.

                  The warrant purchase price (subject to adjustment as noted
below) shall be Four Dollars ($4.00) per share ("Warrant Purchase Price").

                  This Warrant is subject to the following provisions, terms
and conditions:

                  1. The rights represented by this Warrant may be exercised
by the holder hereof, in whole or in part, by written notice of exercise
delivered to the Company and by the surrender of this Warrant (properly
endorsed if required) at the principal office of the Company and upon payment
to it by check of the purchase price for such shares. The Company agrees that
the shares so purchased shall be and are deemed to be issued to the holder
hereof as the record owner of such shares as of the close of business on the
date on which this Warrant shall have been surrendered and payment made for
such shares as aforesaid. Subject to the provisions of the next succeeding
paragraph, certificates for the shares of stock so purchased shall be
delivered to the holder hereof within a reasonable time, not exceeding 10
days, after the rights represented by this Warrant shall have been so
exercised, and, unless this Warrant has expired, a new Warrant representing
the number of shares, if any, with respect to which this Warrant shall not
then have been exercised shall also be delivered to the holder hereof within
such time.

                  2. Notwithstanding the foregoing, however, the Company
shall not be required to deliver any certificate for shares of stock upon
exercise of this Warrant except in accordance with the provisions, and
subject to the limitations, of paragraph 8 hereof.

                  3. The Company represents and warrants that this Warrant
has been duly authorized by all necessary corporate action, has been duly
executed and delivered and is a legal and binding obligation of the Company,
enforceable against the Company in accordance with the terms of this Warrant.
The Company covenants and agrees that all shares which may be issued upon the
exercise of the rights represented by this Warrant according to the terms
hereof or

<PAGE>

represented by the Common Stock will, upon issuance, be duly authorized and
issued, fully paid and nonassessable. The Company further covenants and
agrees that during the period within which the rights represented by this
Warrant may be exercised, the Company will at all times have authorized, and
reserved for the purpose of issue or transfer upon exercise of the
subscription rights evidenced by this Warrant, a sufficient number of shares
of its Common Stock to provide for the exercise of the rights represented by
this Warrant, free from preemptive rights or other actual contingent purchase
rights other than those held by a holder of this Warrant (as a result of
holding this Warrant).

                  4. The Company will pay any documentary stamp taxes
attributable to the issuance of shares of Common Stock upon the exercise of
this Warrant; provided, however, that the Company shall not be required to
pay any tax which may be payable in respect of any transfer involved in the
registration of any certificates for Warrants, or shares of Common Stock
issued upon exercise of this Warrant, in a name other than that of the
Purchaser. The Purchaser shall be responsible for all other tax liability
that may arise as a result of holding or transferring this Warrant or
receiving shares of Common Stock upon exercise hereof.

                  5. The above provisions are, however, subject to the
following:

                           (a) The Warrant Purchase Price shall, from and
after the date of issuance of this Warrant, be subject to adjustment from
time to time as hereinafter provided. Upon each adjustment of the Warrant
Purchase Price, the holder of this Warrant shall thereafter be entitled to
purchase, at the Warrant Purchase Price resulting from such adjustment, the
number of shares obtained by multiplying the Warrant Purchase Price in effect
immediately prior to such adjustment by the number of shares purchasable
pursuant hereto immediately prior to such adjustment and dividing the product
thereof by the warrant purchase price resulting from such adjustment.

                           (b) In case the Company shall (i) declare a
dividend upon the Common Stock payable in Common Stock (other than a dividend
declared to effect a subdivision of the outstanding shares of Common Stock,
as described in subparagraph (b) below) or any obligations or any shares of
stock of the Company which are convertible into or exchangeable for Common
Stock (such obligations or shares of stock being hereinafter referred to as
"Convertible Securities"), or in any rights or options to purchase any Common
Stock or Convertible Securities, or (ii) declare any other dividend or make
any other distribution upon the Common Stock payable otherwise than out of
earnings or earned surplus, then thereafter the holder of this Warrant upon
the exercise hereof will be entitled to receive the number of shares of
Common Stock to which such holder shall be entitled upon such exercise, and,
in addition and without further payment therefor, such number of shares of
Common Stock, such that upon exercise hereof, such holder would receive such
number of shares of Common Stock as a result of each dividend described in
clause (i) above and each dividend or distribution described in clause (ii)
above which such holder would have received by way of any such dividend or
distribution if continuously since the record date for any such dividend or
distribution such holder (i) had been the record holder of the number of
shares of Common Stock then received, and (ii) had retained all dividends or
distributions in stock or securities (including Common Stock or Convertible

                                       2
<PAGE>

Securities, or in any rights or options to purchase any Common Stock or
Convertible Securities) payable in respect of such Common Stock or in respect
of any stock or securities paid as dividends or distributions and originating
directly or indirectly from such Common Stock. For the purposes of the
foregoing, a dividend or distribution other than in cash shall be considered
payable out of earnings or surplus only to the extent that such earnings or
surplus are charged an amount equal to the fair value of such dividend as
determined by the Board of Directors of the Company.

                           (c) In case the Company shall at any time
subdivide its outstanding shares of Common Stock into a greater number of
shares, the Warrant Purchase Price in effect immediately prior to such
subdivision shall be proportionately reduced, and conversely, in case the
outstanding shares of Common Stock of the Company shall be combined into a
smaller number of shares, the Warrant Purchase Price in effect immediately
prior to such combination shall be proportionately increased.

                           (d) If any capital reorganization or
reclassification of the capital stock of the Company, or consolidation or
merger of the Company with another corporation, or the sale of all or
substantially all of its assets to another corporation shall be effected in
such a way that holders of Common Stock shall be entitled to receive stock,
securities or assets with respect to or in exchange for Common Stock, then,
as a condition of such reorganization, reclassification, consolidation,
merger or sale, lawful and adequate provision shall be made whereby the
holder hereof shall thereafter have the right to purchase and receive, upon
the basis and upon the terms and conditions specified in this Warrant and in
lieu of the shares of the Common Stock of the Company immediately theretofore
purchasable and receivable upon the exercise of the rights represented
hereby, such shares of stock, securities or assets as may be issued or
payable with respect to or in exchange for a number of outstanding shares of
such Common Stock equal to the number of shares of such stock immediately
theretofore purchasable and receivable upon the exercise of the rights
represented hereby had such reorganization, reclassification, consolidation,
merger or sale not taken place, and in any such case appropriate provision
shall be made with respect to the rights and interests of the holder of this
Warrant to the end that the provisions hereof (including without limitation
provisions for adjustments of the warrant purchase price and of the number of
shares purchasable upon the exercise of this Warrant) shall thereafter be
applicable, as nearly as may be, in relation to any shares of stock,
securities or assets thereafter deliverable upon the exercise hereof. The
Company shall not effect any such consolidation, merger or sale, unless prior
to the consummation thereof the successor corporation (if other than the
Company) resulting from such consolidation or merger or the corporation
purchasing such assets shall assume, by written instrument executed and
mailed to the registered holder hereof at the last address of such holder
appearing on the books of the Company, the obligation to deliver to such
holder such shares of stock, securities or assets as, in accordance with the
foregoing provisions, such holder may be entitled to purchase.

                           (e) Upon any adjustment of the Warrant Purchase
Price, then and in each such case the Company shall give written notice
thereof, by first-class mail, postage prepaid, addressed to the registered
holder of this Warrant at the address of such holder as shown on the books of
the Company, which notice shall state the Warrant Purchase Price resulting
from

                                       3
<PAGE>

such adjustment and the increase or decrease, if any, in the number of shares
purchasable at such price upon the exercise of this Warrant, setting forth in
reasonable detail the method of calculation and the facts upon which such
calculation is based.

                           (f) In case any time:

                               (i) the Company shall declare any cash
dividend on its capital stock at a rate in excess of the rate of the last
cash dividend theretofore paid;

                               (ii) the Company shall pay any dividend
payable in stock upon its capital stock or make any distribution (other than
regular cash dividends) to the holders of its capital stock;

                               (iii) the Company shall offer for subscription
pro rata to the holders of its capital stock any additional shares of stock
of any class or other rights;

                               (iv) there shall be any capital
reorganization, or reclassification of the capital stock of the Company, or
consolidation or merger of the Company with, or sale of all or substantially
all of its assets to, another corporation; or

                               (v) there shall be a voluntary or involuntary
dissolution, liquidation or winding up of the Company;

then, in any one or more of said cases, the Company shall give written
notice, by first-class mail, postage prepaid, addressed to the registered
holder of this Warrant at the address of such holder as shown on the books of
the Company, of the date on which (aa) the books of the Company shall close
or a record shall be taken for such dividend, distribution or subscription
rights, or (bb) such reorganization, reclassification, consolidation, merger,
sale, dissolution, liquidation or winding up, or conversion or redemption
shall take place, as the case may be. Such notice shall also specify the date
as of which the holders of capital stock of record shall participate in such
dividend, distribution or subscription rights, or shall be entitled to
exchange their capital stock for securities or other property deliverable
upon such reorganization, reclassification, consolidation, merger, sale,
dissolution, liquidation or winding up, or conversion or redemption, as the
case may be. Such written notice shall be given at least 20 days prior to the
action in question and not less than 20 days prior to the record date or the
date on which the Company's transfer books are closed in respect thereto.

                           (g) If any event occurs as to which in the opinion
of the Board of Directors of the Company the other provisions of this
paragraph 5 are not strictly applicable or if strictly applicable would not
fairly protect the purchase rights of the holder of this Warrant or of Common
Stock in accordance with the essential intent and principles of such
provisions, then the Board of Directors shall make an adjustment in the
application of such provisions, in accordance with such essential intent and
principles, so as to protect such purchase rights as aforesaid.

                  6. This Warrant shall not entitle the holder hereof to any
voting rights or other rights as a stockholder of the Company.

                                       4
<PAGE>

                  7. The holder of this Warrant, by acceptance hereof, agrees
to give written notice to the Company before transferring this Warrant or
transferring any Common Stock issuable or issued upon the exercise hereof of
such holder's intention to do so, describing briefly the manner of any
proposed transfer of this Warrant or such holder's intention as to the
disposition to be made of shares of Common Stock issuable or issued upon the
exercise hereof. Such holder shall also provide the Company with an opinion
of counsel satisfactory to the Company to the effect that the proposed
transfer of this Warrant or disposition of shares may be effected without
registration or qualification (under any Federal or State law) of this
Warrant or the shares of Common Stock issuable or issued upon the exercise
hereof. Upon receipt of such written notice and opinion by the Company, such
holder shall be entitled to transfer this Warrant, or to exercise this
Warrant in accordance with its terms and dispose of the shares received upon
such exercise or to dispose of shares of Common Stock received upon the
previous exercise of this Warrant, all in accordance with the terms of the
notice delivered by such holder to the Company, provided that an appropriate
legend respecting the aforesaid restrictions on transfer and disposition may
be endorsed on this Warrant or the certificates for such shares.

                  8. Subject to the provisions of paragraph 7 hereof, this
Warrant and all rights hereunder are transferable, in whole or in part, at
the principal office of the Company by the holder hereof in person or by duly
authorized attorney, upon surrender of this Warrant properly endorsed. Each
taker and holder of this Warrant, by taking or holding the same, consents and
agrees that the bearer of this Warrant, when endorsed, may be treated by the
Company and all other persons dealing with this Warrant as the absolute owner
hereof for any purpose and as the person entitled to exercise the rights
represented by this Warrant, or to the transfer hereof on the books of the
Company, any notice to the contrary notwithstanding; but until such transfer
on such books, the Company may treat the registered holder hereof as the
owner for all purposes.

                  9. This Warrant is exchangeable, upon the surrender hereof
by the holder hereof at the principal office of the Company, for new Warrants
of like tenor representing in the aggregate the right to subscribe for and
purchase the number of shares which may be subscribed for and purchased
hereunder, each of such new Warrants to represent the right to subscribe for
and purchase such number of shares as shall be designated by said holder
hereof at the time of such surrender.

                  10.      The Company covenants and agrees as follows:

                           (a)      For purposes of this Section 10:

                               (i) The term "register", "registered" and
"registration" refer to a registration effected by preparing and filing a
registration statement or similar document in compliance with the Securities
Act, and the declaration or ordering of effectiveness of such registration
statement or document;

                               (ii) The term "Registrable Securities" means
(1) the Common Stock issuable or issued upon exercise of this Warrant; and
(2) any Common Stock of the Company issued as (or issuable upon the
conversion or exercise of any warrant, right or other security which is
issued as) a dividend or other distribution with respect to, or in exchange
for or

                                       5
<PAGE>

in replacement of, such Common Stock; PROVIDED, HOWEVER, that Common Stock or
other securities shall only be treated as Registrable Securities if and so
long as (A) they have not been sold to or through a broker or dealer or
underwriter in a public distribution or a public securities transaction, and
(B) they have not been sold in a transaction exempt from the registration and
prospectus delivery requirements of the Securities Act under Section 4(1)
thereof so that all transfer restrictions and restrictive legends with
respect thereto are removed upon the consummation of such sale;

                               (iii) "Registration Statement" means the
registration statement on Form S-3 which the Company is obligated to prepare
and file with the Securities and Exchange Commission ("SEC") pursuant to
Section 6 of Annex I of the Stock Purchase Agreement, dated as of March 21,
2001, by and between the Purchaser and the Company.

                               (iv) "Securities Act" means the Securities Act
of 1933, as amended.

                               (v) The term "Securities Holder" means any
person owning or having the right to acquire Registrable Securities or any
assignee thereof, including without limitation and without need for an
express assignment, subsequent holders of Registrable Securities; and

                               (vi) The term "Form S-3" means such form under
the Securities Act as in effect on the date hereof or any registration form
under the Securities Act subsequently adopted by the SEC which permits
inclusion or incorporation of substantial information by reference to other
documents filed by the Company with the SEC.

                           (b) The Company shall register the Registrable
Securities on the Registration Statement.

                           (c) The Company shall bear and pay all expenses
incurred in connection with any registration, filing or qualification of
Registrable Securities with respect to a registration pursuant to Section
10(b) for each Securities Holder, including (without limitation) all
registration, filing and qualification fees, printers and accounting fees
relating or apportionable thereto and the fees and disbursements of one
counsel for the selling Securities Holders selected by them, but excluding
underwriting discounts and commissions relating to Registrable Securities.

                           (d) In the event any Registrable Securities are
included in a registration statement under this Section 10:

                               (i) The Company will indemnify and hold
harmless each Securities Holder, any underwriter (as defined in the
Securities Act) for such Securities Holder and each person, if any, who
controls such Securities Holder or underwriter within the meaning of the
Securities Act or the Securities Exchange Act of 1934, as amended (the "1934
Act"), against any losses, claims, damages or liabilities (joint or several)
to which they may become subject under the Securities Act, or the 1934 Act or
other federal or state law, insofar as such

                                       6
<PAGE>

losses, claims, damages or liabilities (or actions in respect thereof) arise
out of or are based upon any of the following statements, omissions or
violations (collectively a "Violation"): (1) any untrue statement or alleged
untrue statement of a material fact contained in the Registration Statement,
including any preliminary prospectus or final prospectus contained therein or
any amendments or supplements thereto, (2) the omission or alleged omission
to state therein a material fact required to be stated therein, or necessary
to make the statements therein not misleading, or (3) any violation or
alleged violation by the Company of the Securities Act, the 1934 Act, any
state securities law or any rule or regulation promulgated under the
Securities Act, or the 1934 Act or any state securities law; and the Company
will pay to each such Securities Holder, underwriter or controlling person,
as incurred, any legal or other expenses reasonably incurred by one law firm
retained by them (or such additional law firms retained by a Securities
Holder or Securities Holders if such Securities Holder or Securities Holders
reasonably believe there exists a conflict of interest among them) in
connection with investigating or defending any such loss, claim, damage,
liability or action; PROVIDED, HOWEVER, that the indemnity agreement
contained in this subsection 10(d)(i) shall not apply to amounts paid in
settlement of any such loss, claim, damage, liability or action if such
settlement is effected without the consent of the Company (which consent
shall not be unreasonably withheld), nor shall the Company be liable in any
such case for any such loss, claim, liability or action to the extent that it
arises out of or is based upon a Violation which occurs in reliance upon and
in conformity with written information furnished expressly for use in
connection with such registration by any such Securities Holder, underwriter
or controlling person.

                               (ii) Each selling Securities Holder will
indemnify and hold harmless the Company, each of its directors, each of its
officers who has signed the Registration Statement, each person, if any, who
controls the Company within the meaning of the Securities Act, any
underwriter, any other Securities Holder selling securities in the
Registration Statement and any controlling person of any such underwriter or
other Securities Holder, against any losses, claims, damages or liabilities
(joint or several) to which any of the foregoing persons may become subject,
under the Securities Act, or the 1934 Act or other federal or state law,
insofar as such losses, claims, damages, or liabilities (or actions in
respect thereto) arise out of or are based upon any Violation, in each case
to the extent (and only to the extent) that such Violation occurs in reliance
upon and in conformity with written information furnished by such Securities
Holder expressly for use in connection with such registration; and each such
Securities Holder will pay, as incurred, any legal or other expenses
reasonably incurred by any person intended to be indemnified pursuant to this
subsection 10(d)(ii), in connection with investigating or defending any such
loss, claim, damage, liability or action; PROVIDED, HOWEVER, that the
indemnity agreement contained in this subsection 10(d)(ii) shall not apply to
amounts paid in settlement of any such loss, claim, damage, liability or
action if such settlement is effected without the consent of the Securities
Holder, which consent shall not be unreasonably withheld; and PROVIDED,
FURTHER that, in no event shall any indemnity under this subsection 10(d)(ii)
exceed the net proceeds from the offering received by such Securities Holder.

                               (iii) Promptly after receipt by an indemnified
party under this Section 10(d) of notice of the commencement of any action
(including any governmental action), such indemnified party will, if a claim
in respect thereto is to be made against any indemnified

                                       7
<PAGE>

party under this Section 10(d), deliver to the indemnified party a written
notice of the commencement thereof and the indemnified party shall have the
right to participate in, and, to the extent the indemnified party so desires,
jointly with any other indemnified party similarly noticed, to assume the
defense thereof with counsel mutually satisfactory to the parties; PROVIDED,
HOWEVER, that an indemnified party (together with all other indemnified
parties which may be represented without conflict by one counsel) shall have
the right to retain one separate counsel, with the fees and expenses to be
paid by the indemnifying party, if representation of such indemnified party
by the counsel retained by the indemnifying party would be inappropriate due
to actual or potential differing interests between such indemnified party and
any other party represented by such counsel in such proceeding. The failure
to deliver written notice to the indemnifying party within a reasonable time
of the commencement of any such action, if prejudicial to its ability to
defend such action, shall relieve such indemnifying party of any liability to
the indemnified party under this Section 10(d), but the omission so to
deliver written notice to the indemnifying party will not relieve it of any
liability that it may have to any indemnified party otherwise than under this
Section 10(d).

                               (iv) The obligations of the Company and
Securities Holders under this Section 10(d) shall survive the completion of
any offering of Registrable Securities in a registration statement under this
Section 10, and otherwise.

                           (e)  With a view to making available to the
Securities Holder the benefits of Rule 144 promulgated under the Securities
Act and any other rule or regulation of the SEC that may at any time permit a
Securities Holder to sell securities of the Company to the public without
registration or pursuant to a registration on Form S-3, the Company agrees to:

                               (i) make and keep public information
available, as those terms are understood and defined in SEC Rule 144, at all
times;

                               (ii) maintain its qualification for
registration on Form S-3 for the sale of the Registrable Securities;

                               (iii) file with the SEC in a timely manner all
reports and other documents required by the Company under the Securities Act
and the 1934 Act; and

                               (iv) furnish to any Securities Holder, so long
as the Securities Holder owns any Registrable Securities, forthwith upon
request (1) a written statement by the Company that it has complied with the
reporting requirements of SEC Rule 144, the Securities Act and the 1934 Act,
or that it qualifies as a registrant whose securities may be resold pursuant
to Form S-3, (2) a copy of the most recent annual or quarterly report of the
Company and such other reports and documents so filed by the Company, and (3)
such other information as may be reasonably requested in availing any
Securities Holder of any rule or regulation of the SEC which permits the
selling of any such securities without registration or pursuant to such form.

                           (f) Any provision of this Section 10 may be
amended and the observance thereof may be waived (either generally or in a
particular instance and either retroactively or prospectively), only with the
written consent of the Company and the Securities

                                       8
<PAGE>

Holders owning a majority of the Registrable Securities then outstanding. Any
amendment or waiver effected in accordance with this paragraph shall be
binding upon each Securities Holder of any Registrable Securities then
outstanding, each future Securities Holder of all such Registrable
Securities, and the Company.

                           (g) No Securities Holder shall be entitled to
exercise any right provided for in Section 10(b) or (c) at such time as all
Registrable Securities held by such Securities Holder can be sold within a
given three-month period without compliance with the registration
requirements of the Securities Act pursuant to Rule 144.

                  11. (a) (a) In addition to and without limiting the rights
of the holder of this Warrant under the terms of this Warrant, the holder of
this Warrant shall have the right to convert this Warrant (the "Conversion
Right") or any portion thereof into shares of Common Stock as provided in
this paragraph 11 at any time or from time to time prior to its expiration.
Upon exercise of the Conversion Right with respect to a particular number of
shares of Common Stock subject to this Warrant (the "Converted Warrant
Shares") and payment of the Warrant Purchase Price multiplied by such number
of Converted Warrant Shares (the "Conversion Payment"), the Company shall
deliver to the holder of this Warrant certificates evidencing such shares of
Common Stock. No fractional shares shall be issuable upon exercise of the
Conversion Right.

                           (b) The Conversion Right may be exercised by the
holder of this Warrant by the surrender of this Warrant at the principal
office of the Company and payment of the Conversion Payment together with a
written statement specifying that the holder thereby intends to exercise the
Conversion Right and indicating the number of shares subject to this Warrant
which are being surrendered (referred to in paragraph (a) above as the
Converted Warrant Shares) in exercise of the Conversion Right. Such
conversion shall be effective upon receipt by the Company of this Warrant
together with the aforesaid Conversion Payment and written statement, or on
such later date as is specified therein (the "Conversion Date"), but not
later than the expiration date of this Warrant. Certificates for the shares
of Common Stock issuable upon exercise of the Conversion Right, and, in the
case of a partial exercise, a new warrant evidencing the shares remaining
subject to this Warrant, shall be issued as of the Conversion Date and shall
be delivered to the holder of this Warrant within 15 days following the
Conversion Date.

                  12. All questions concerning this Warrant will be governed
and interpreted and enforced in accordance with the internal law, not the law
of conflicts, of the State of New York.

                                       9
<PAGE>

                  IN WITNESS WHEREOF, Endocardial Solutions, Inc. has caused
this Warrant to be signed by its duly authorized officer and this Warrant to
be dated as of March 26, 2001.

                                  ENDOCARDIAL SOLUTIONS, INC.

                                  By     /s/ James W. Bullock
                                    -------------------------------------------
                                     Its  President and Chief Executive Officer
                                        ---------------------------------------

                             RESTRICTION ON TRANSFER

                  "The securities evidenced hereby may not be transferred
without (i) the opinion of counsel satisfactory to this corporation that such
transfer may be lawfully made without registration under the Federal
Securities Act of 1933 and all applicable state securities laws or (ii) such
registration."

<PAGE>

SUBSCRIPTION FORM

           TO BE EXECUTED BY THE HOLDER OF THIS WARRANT IF SUCH HOLDER
             DESIRES TO EXERCISE THIS WARRANT IN WHOLE OR IN PART:

To:      Endocardial Solutions, Inc. (the "Company")

               THE UNDERSIGNED ___________________________________

                     PLEASE INSERT SOCIAL SECURITY OR OTHER
                        IDENTIFYING NUMBER OF SUBSCRIBER:

                        __________________________________

hereby irrevocably elects to exercise the right of purchase represented by
this Warrant for, and to purchase thereunder, ___________ shares of the
Common Stock (the "Common Stock") provided for therein and tenders payment
herewith to the order of the Company in the amount of $___________, such
payment being made as provided on the face of this Warrant.

                  The undersigned requests that certificates for such shares
of Common Stock be issued as follows:

Name:  _______________________________________________________________________

Address:  ____________________________________________________________________

Deliver to:  _________________________________________________________________

Address:  ____________________________________________________________________

and, if such number of shares of Common Stock shall not be all the shares of
Common Stock purchasable hereunder, that a new Warrant for the balance
remaining of the shares of Common Stock purchasable under this Warrant be
registered in the name of, and delivered to, the undersigned at the address
stated above.

Dated: __________________

                 Signature ___________________________________________________
                     Note:  The signature on this Subscription Form must
                     correspond with the name as written upon the face of this
                     Warrant in every particular, without alteration or
                     enlargement or any change whatever.

                                       11
<PAGE>

                               FORM OF ASSIGNMENT
                       (TO BE SIGNED ONLY UPON ASSIGNMENT)

                  FOR VALUE RECEIVED, the undersigned hereby sells, assigns
and transfers unto this Warrant, and appoints to transfer this Warrant on the
books of the Company with the full power of substitution in the premises.

Dated:  _______________

In the presence of:

                         _____________________________________________________

                         (Signature must conform in all respects to the name
                         of the holder as specified on the face of this
                         Warrant without alteration, enlargement or any change
                         whatsoever, and the signature must be guaranteed in
                         the usual manner)

                                       12

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00023-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00023-of-00352.parquet"}]]